StockNews.com Begins Coverage on TG Therapeutics (NASDAQ:TGTX)

StockNews.com initiated coverage on shares of TG Therapeutics (NASDAQ:TGTX – Get Rating) in a research report sent to investors on Thursday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

A number of other research analysts have also recently issued reports on the stock. B. Riley lifted their price objective on shares of TG Therapeutics from $17.00 to $23.00 and gave the company a buy rating in a research note on Friday, December 30th. Evercore ISI lifted their price objective on shares of TG Therapeutics from $16.00 to $25.00 and gave the company an outperform rating in a research note on Tuesday, January 24th. Bank of America lifted their price objective on shares of TG Therapeutics from $5.00 to $6.00 and gave the company an underperform rating in a research note on Thursday, December 29th. Cantor Fitzgerald raised their target price on shares of TG Therapeutics from $18.00 to $24.00 and gave the company an overweight rating in a research report on Tuesday, February 7th. Finally, The Goldman Sachs Group raised their target price on shares of TG Therapeutics from $4.00 to $6.00 and gave the company a sell rating in a research report on Friday, December 30th. Three research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of Hold and a consensus price target of $18.00.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX opened at $14.79 on Thursday. The company’s 50 day simple moving average is $15.65 and its 200 day simple moving average is $10.21. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.16 and a quick ratio of 3.16. TG Therapeutics has a 1 year low of $3.48 and a 1 year high of $19.59.

Insider Transactions at TG Therapeutics

In other news, Director Laurence N. Charney sold 30,000 shares of TG Therapeutics stock in a transaction on Wednesday, January 4th. The shares were sold at an average price of $11.10, for a total transaction of $333,000.00. Following the transaction, the director now owns 234,729 shares in the company, valued at $2,605,491.90. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, Director Laurence N. Charney sold 30,000 shares of TG Therapeutics stock in a transaction on Wednesday, January 4th. The shares were sold at an average price of $11.10, for a total transaction of $333,000.00. Following the transaction, the director now owns 234,729 shares in the company, valued at $2,605,491.90. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Yann Echelard purchased 9,000 shares of the business’s stock in a transaction dated Friday, January 6th. The shares were acquired at an average price of $10.64 per share, for a total transaction of $95,760.00. Following the acquisition, the director now owns 201,848 shares of the company’s stock, valued at approximately $2,147,662.72. The disclosure for this purchase can be found here. 8.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds have recently bought and sold shares of TGTX. Belpointe Asset Management LLC bought a new position in TG Therapeutics during the fourth quarter worth $25,000. Fifth Third Bancorp bought a new position in TG Therapeutics during the third quarter worth $27,000. WJ Interests LLC bought a new position in TG Therapeutics during the fourth quarter worth $35,000. Allspring Global Investments Holdings LLC raised its stake in TG Therapeutics by 517.1% during the third quarter. Allspring Global Investments Holdings LLC now owns 6,603 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 5,533 shares during the last quarter. Finally, Great West Life Assurance Co. Can bought a new position in TG Therapeutics during the third quarter worth $40,000. Institutional investors own 68.06% of the company’s stock.

About TG Therapeutics

(Get Rating)

TG Therapeutics, Inc engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.